ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Dominique H. Grunenwald
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grunenwald, D. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Grunenwald, D. H.

Ann Thorac Surg 2003;76:1815
© 2003 The Society of Thoracic Surgeons

Invited commentary

Dominique H. Grunenwald, MD

Department of Thoracic Surgery, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, Paris 75014, France

e-mail: thorax@imm.fr

The first 20% of the full text of this article appears below.

Doctor Ichinose and colleagues opportunely point out several current controversial topics: (1) benefit of surgery in stage IIIB disease; (2) feasibility of surgical resection after CRT; (3) rationale of using UFT (a combination of Tegafur and Uracile) concurrently with Cisplatin and radiation therapy; (4) relevance of the T4 descriptor in present staging system; (5) coherence of team skills for multicentric trials.

Stage IIIB disease includes several situations in which surgical resection can be performed as an adjuvant local control after CRT. This is currently shown and particularly quoted in the paper by Ichinose and colleagues. For instance, . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.